

## 1 NGLY1 Deficiency: A Prospective Natural History Study (NHS)

2 Sandra Tong<sup>2</sup>, Pamela Ventola<sup>3,4</sup>, Christina H. Frater<sup>1</sup>, Jenna Klotz<sup>1</sup>, Jennifer M. Phillips<sup>1</sup>,  
3 Srikanth Muppidi<sup>1</sup>, Selina S. Dwight<sup>2</sup>, William F. Mueller<sup>2</sup>, Brendan J. Beahm<sup>2</sup>, Matt Wilsey<sup>2</sup>,  
4 Kevin J. Lee<sup>2</sup>

5 <sup>1</sup>Department of Neurology, Stanford University, Stanford, CA, USA 94305

6 <sup>2</sup>Grace Science Foundation, Menlo Park, CA, 94305

7 <sup>3</sup>Cogstate, New Haven, CT, 06510

8 <sup>4</sup>Yale Child Study Ctr, New Haven, CT, 06519

9 \*Corresponding Author: [kevin@gracescience.org](mailto:kevin@gracescience.org); 646-847-8533

10

## 11 **Abstract**

12 N-glycanase 1 (NGLY1) Deficiency is a debilitating, ultra-rare autosomal recessive disorder  
13 caused by loss of function of NGLY1, a cytosolic enzyme that deglycosylates other proteins. It is  
14 characterized by severe global developmental delay and/or intellectual disability, hyperkinetic  
15 movement disorder, transient elevation of transaminases, (hypo)alacrima, and progressive,  
16 diffuse, length-dependent sensorimotor polyneuropathy. A prospective natural history study  
17 (NHS) was conducted to elucidate clinical features and disease course. Twenty-nine participants  
18 were enrolled (15 onsite, 14 remotely) and followed for up to 32 months, representing ~29% of  
19 the ~100 patients identified worldwide. Participants exhibited profound developmental delays,

20 with almost all developmental quotients below 20 on the Mullen Scales of Early Learning, well  
21 below the normative score of 100. Increased difficulties with sitting and standing suggested  
22 decline in motor function over time. Most patients presented with (hypo)alacrima and reduced  
23 sweat response. Pediatric quality of life was poor except for emotional function.  
24 Language/communication and motor skill problems including hand use were reported by  
25 caregivers as the most bothersome symptoms. Levels of the substrate biomarker, GlcNAc-Asn  
26 (aspartylglucosamine; GNA), were consistently elevated in all participants over time,  
27 independent of age. Liver enzymes were elevated for some participants but improved especially  
28 in younger patients and did not reach levels indicating severe liver disease. Three participants  
29 died during the study period. Data from this NHS informs selection of endpoints and assessments  
30 for future clinical trials for NGLY1 Deficiency interventions. Potential endpoints include GNA  
31 biomarker levels, neurocognitive assessments, autonomic and motor function (particularly hand  
32 use), (hypo)alacrima, and quality of life.

### 33 **Introduction**

34 *N*-glycanase 1 (NGLY1) Deficiency (OMIM [615273](#)) is a severely debilitating, ultra-rare,  
35 autosomal recessive neurodevelopmental disorder characterized by five core clinical features:  
36 global developmental delay and/or intellectual disability, a hyperkinetic movement disorder,  
37 transient elevation of transaminases, (hypo)alacrima, and a progressive, diffuse, length-  
38 dependent sensorimotor polyneuropathy ([Adams 2018](#); [Enns 2014](#); [Lam 2018](#)). In addition to  
39 these five core features, individuals may experience seizures, reduced ability to sweat, skeletal  
40 problems such as contractures, scoliosis, and skeletal deformities, hearing loss, vision  
41 impairment, and adrenal insufficiency ([Lam 2018](#)). There are approximately 100 individuals  
42 living with NGLY1 Deficiency identified globally ([Pandey 2022](#)). Because so few cases have  
43 been identified, estimated lifespan is unknown. While some individuals survive into early  
44 adulthood, there have been reports of death during infancy and adolescence ([Lam 2018](#), [Dabaj](#)  
45 [2021](#), [Kalfon 2021](#), [Stuut 2021](#)). Most affected individuals require constant daily care due to  
46 difficulty performing activities such as feeding, toileting, and bathing, and many are unable to  
47 walk or speak ([Lam 2018](#)).

48 NGLY1 Deficiency is caused by mutations in the *NGLY1* gene that encodes the cytosolic protein  
49 *N*-glycanase 1, or NGLY1 ([Enns 2014](#)). NGLY1 cleaves *N*-glycans from proteins targeted for  
50 degradation as part of the endoplasmic reticulum-associated degradation (ERAD) pathway.

51 ERAD is a cellular quality control pathway in which misfolded or improperly processed proteins  
52 in the endoplasmic reticulum (ER) are translocated to the cytosol and delivered to the  
53 proteasome for degradation. NGLY1 cleaves N-linked glycans from ERAD substrate  
54 glycoproteins by hydrolyzing the proximal N-acetylglucosamine-asparagine (GlcNAc-Asn)

55 amide bond prior to degradation by the proteasome. This cleavage results in two products, a free  
56 oligosaccharide and a deaminated protein (Suzuki 2016). In the absence of NGLY1, glycans can  
57 be cleaved from the protein at alternate positions within the glycan, resulting in an incompletely  
58 deglycosylated protein that retains the proximal GlcNAc bound to Asn. This protein can then be  
59 degraded to peptides, which are hydrolyzed to amino acids. Because the substrate GlcNAc-Asn  
60 bond normally cleaved by NGLY1 remains intact, GlcNAc-Asn (GNA) accumulates in the  
61 cytosol in cells that lack NGLY1 activity (Hajjes 2019; Mueller 2022). As a consequence, GNA  
62 levels are consistently elevated in NGLY1 deficient organisms and cells (Mueller 2022) and can  
63 be measured using a quantitative assay in dried blood spots, urine, and plasma samples from  
64 NGLY1 Deficiency patients (Hajjes 2019; Mueller 2022).

65 Restoration of NGLY1 activity in NGLY1 deficient cellular and animal models leads to a  
66 reduction of GNA levels. Thus measurement of GNA concentration directly reflects NGLY1  
67 activity and could be expected to predict clinically meaningful restoration of NGLY1 activity in  
68 a therapeutic setting (Hajjes 2019; Mueller 2022; Zhu 2022). A reliable biomarker for NGLY1  
69 Deficiency is critical given the small population of affected individuals, the slowly progressive  
70 nature of the disease, and the high degree of phenotypic variability (Mueller 2022).

71 The specific factors underlying the heterogenous presentation of NGLY1 Deficiency are not  
72 known. Diagnosis of NGLY1 Deficiency is based on a combination of genetic testing, a detailed  
73 medical history, and clinical examination to identify key clinical features, particularly  
74 (hypo)alacrima, which is only present in very few disorders. Increased levels of plasma or urine  
75 GNA may support a diagnosis of NGLY1 Deficiency when genetic testing shows variants of  
76 uncertain significance (Hajjes 2019; Mueller 2022). Given the rarity of the disease and its

77 heterogenous nature, there is often a significant delay between onset of symptoms and diagnosis  
78 ([Enns 2014](#), [Adams 2018](#)).

79 There are no approved treatments for NGLY1 Deficiency; rather, symptoms must be managed  
80 daily by caretakers. Symptomatic treatments include feeding tubes to provide nutrients;  
81 lubricating eye drops or ointments for dry eyes related to poor tear production; anti-seizure  
82 medication; occupational, physical, and speech therapy to assist with activities of daily living;  
83 and psychosocial support for families and caregivers ([Lam 2018](#); [Lam 2017](#)). Nearly half of  
84 patients also require invasive procedures or surgery for musculoskeletal issues associated with  
85 NGLY1 Deficiency ([Cahan 2019](#)).

86 To support the development of disease-modifying therapies, a full elucidation of the natural  
87 history and clinical manifestations of NGLY1 Deficiency is needed. As the disorder was  
88 recently identified ([Need 2012](#)), a prospective natural history study (NHS) that enrolled a  
89 substantial portion of the known affected individuals was conducted to improve understanding of  
90 the presentation and course of the disorder.

91 This paper reports on the findings of the NGLY1 Deficiency prospective NHS described above  
92 ([NCT03834987](#)). The objectives of this study were to understand the clinical spectrum and  
93 progression of NGLY1 Deficiency using standardized clinical and neurodevelopmental  
94 assessments, and to identify and define clinical and biomarker endpoints for use in therapeutic  
95 trials.

## 96 **Materials and Methods**

### 97 **Study design**

98 The NGLY1 NHS reported here was a prospective, longitudinal observational study conducted  
99 by Stanford University (<http://clinicaltrials.gov>, NCT03834987) and funded by the Grace  
100 Science Foundation ([gracescience.org](http://gracescience.org)), a research and advocacy group for NGLY1 Deficiency.  
101 The planned enrollment was up to 50 patients with a confirmed diagnosis of NGLY1 Deficiency,  
102 with up to 15 time points per participant. Study procedures included annual in-person (“onsite”  
103 participants) or annual remote (“remote” participants) evaluations along with remote assessments  
104 for each group every 4-months between annual evaluations. Established developmental and  
105 health-related quality of life (HRQoL) measures as well as standardized laboratory and clinical  
106 assessments were employed.

## 107 **Participants**

108 Participants included males and females of any age with a suspected or confirmed diagnosis of  
109 NGLY1 Deficiency based on the identification of (likely) pathogenic variants in both *NGLY1*  
110 alleles and clinical characteristics consistent with the disease. Parent(s)/legal representative(s) of  
111 participants were required to give informed consent/assent for study participation; for the results  
112 of the study to be presented at scientific/medical meetings or published in scientific journals; and  
113 to be willing for the participant to provide clinical data, provide biological samples, and  
114 participate in standardized assessments. Willingness to travel to Palo Alto, CA was favored, but  
115 not required. Each study participant’s data records were assigned a unique code number.  
116 Information about the code was kept in a secure location and access was limited to key research  
117 study personnel.

118 Participants were excluded from the study if they had a second, confirmed disorder affecting  
119 neurodevelopment or with overlapping symptoms of NGLY1 Deficiency.

120 Participants were permitted to be enrolled as “onsite” or “remote” participants. Onsite  
121 participants were scheduled to visit the clinical site once per year for the study duration, with 2  
122 telephone / video visits in between each annual visit at 4-month intervals. Remote participants  
123 were scheduled for annual telephone / video visit with 2 telephone / video visits in between each  
124 annual visit at 4-month intervals. Most assessments began at baseline, except for SSDS,  
125 Schirmer’s test, and the question about the most bothersome symptom, which began in Year 2.  
126 These assessments therefore have a lower number of data points.

127 Participants enrolled in the study at different times (between February 15, 2019 and October 14,  
128 2020); however, the end date of the study was the same for all patients. For this reason, the  
129 number of participants with an assessment at each study time point was variable and generally  
130 decreased over time. This effect was compounded by the COVID-19 pandemic, which caused  
131 delays in enrollment and assessments.

## 132 **Assessments**

### 133 *Primary Objectives*

134 There were two primary outcome measures for the NGLY1 Deficiency NHS: 1) developmental  
135 assessment at baseline and longitudinally, as measured by the established scales, and 2) disease  
136 course over time as measured by standardized medical histories.

137 The following established scales were used for the primary outcome capturing development  
138 assessment: Mullen Scales of Early Learning (MSEL), Vineland Adaptive Behavior Scales, 3<sup>rd</sup>  
139 Edition (Vineland-3), Peabody Scales of Motor Development (PDMS-2), and Beery-Buktenica  
140 Test of Visual Motor Integration (Beery VMI).

141 The MSEL is a direct assessment and provides a broad global assessment of development in  
142 children from birth to 68 months by examining 5 key subscales: gross motor, fine motor, visual  
143 reception, expressive language, and receptive language. The developmental quotient (DQ),  
144 which is calculated by averaging the 5 areas of the Mullen scale and dividing the developmental  
145 age by the chronological age x 100 (a DQ of 100 corresponds to an exact match between the  
146 developmental and chronological age), provides an overall approximation of the affected  
147 individual's ability to function ([Aylward 2008](#)).

148 The Vineland-3 is a parent/caregiver-reported measure that uses a semi-structured interview to  
149 assess adaptive behavior across four domains: Communication, Daily Living Skills,  
150 Socialization, and Motor Skills. It is used to support the diagnosis of intellectual and  
151 developmental disabilities ([Farmer 2020](#)). The Vineland Adaptive Behavior Composite is  
152 derived from the Communication, Daily Living Skills, and Socialization domains.

153 The PDMS-2 includes five subscales used to calculate 2 quotients: Grasping and Visual–Motor  
154 Integration (which are used to calculate the Fine Motor Quotient [FMQ]); and Stationary,  
155 Locomotion and Object Manipulation, replaced by the Reflexes subtest for children up to eleven  
156 months old (which are used to calculate the Gross Motor Quotient [GMQ]). FMQ and GMQ can  
157 also be combined to yield a Total Motor Quotient (TMQ). FMQ, GMQ, and TMQ are scored  
158 similarly to the DQ. They compare developmental age to chronological age; a score of 100  
159 represents an exact match between developmental age and chronological age. Scores that are  
160 lower or higher than 100 represent a developmental age that is lower or higher than the  
161 chronological age, respectively ([Rebelo 2021](#)).



162 The Beery VMI is administered by a clinician and assesses the ability to integrate visual and  
163 motor activities in individuals 2 years of age and older. It requires individuals to copy a sequence  
164 of geometric forms using paper and pencil. While the Beery VMI was a planned assessment for  
165 this NHS, participants in the study were too developmentally impaired to attempt this test  
166 ([Spencer 2010](#)).

167 The Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT-2) and Differential  
168 Ability Scales-II (DAS-2) were used for higher functioning subjects but are not discussed in this  
169 paper because they were only conducted in 3 participants.

170 The primary outcome measure of disease course over time was measured by collecting  
171 standardized medical histories that included general physical evaluations, clinical neurologic  
172 evaluations, standardized dysmorphology evaluations, laboratory studies (comprehensive  
173 metabolic panel, liver function tests, creatine kinase, lactic acid, fasting lipid panel,  
174 adrenocorticotrophic hormone [ACTH], cortisol, biochemical studies), scoring of movement  
175 disorders (including 10-meter walk test [10-MWT]), and standardized and Schirmer's  
176 ophthalmologic evaluations.

177 Schirmer's test was used to evaluate (hypo)alacrimalia. This test determines whether the eye  
178 produces sufficient tears by placing calibrated test strips of non-toxic filter paper within the  
179 lower eyelid of each eye for 5 minutes and measuring the distance traveled by the tears on the  
180 test strips ([Karampatakis 2010](#)).

181 The sitting and standing abilities were part of the neurologic exam and used to measure gross  
182 motor function ([Pereira 2016](#)). Minimal support was defined as hands only, and maximal support  
183 was the requirement for truncal support. The 10-MWT was used to measure walking speed in

184 meters per second over a short walking distance at an individual's usual walking speed  
185 (comfortable speed) and/or walking as quickly as possible (fast speed) ([de Baptista 2020](#)).

### 186 *Secondary Objectives*

187 Secondary objectives included identification of clinical endpoints or biomarkers for therapeutic  
188 trials, and caregiver and participant QoL at baseline and longitudinally. Participant QoL was  
189 measured through the Pediatric Quality of Life Inventory (PedsQL) as reported by the caregiver.  
190 The PedsQL measures quality of life in children and adolescents; it includes 23 questions in 4  
191 domains: physical, emotional, social, and school functioning. Caregiver QoL was measured  
192 through self-report using SF-36. The SF-36 measures quality of life in adults, adolescents, and  
193 children and includes 36 questions in 8 domains: vitality, physical functioning, bodily pain,  
194 general health perceptions, physical role functioning, emotional role functioning, social role  
195 functioning, and mental health. Finally, a single question asking caregivers to identify the most  
196 bothersome symptom for the participant was included.

197 Other procedures completed at baseline and longitudinally as tolerated included:  
198 electroencephalogram (EEG), seizure diary (when applicable for those experiencing active  
199 seizures), nerve conduction studies, and quantitative studies of autonomic function (QSART).  
200 EEG and seizure diary results are reported in a separate paper ([Levy 2022](#)).

### 201 *Biomarker*

202 The assay for GNA substrate biomarker has been described previously ([Mueller 2022](#)). This  
203 assay uses liquid chromatography/tandem mass spectrometry (LC/MS/MS) in positive  
204 electrospray ionization mode (ESI+) for the quantitation of GNA in human plasma. Test

205 samples, calibration standards, and QC samples were processed by protein precipitation with  
206 acetonitrile to enrich the analyte in the matrix samples. Samples were homogenized in  
207 phosphate-buffered saline (PBS) and mixed with three volumes of ice cold Internal Standard  
208 Solution (acetonitrile containing 60 ng/ml d3-GNA, Omicron Biochemicals, Inc.; catalog  
209 number AAG-004, Lot# Q01-N0816). They were then centrifuged at 6100 g for 30 min. An  
210 aliquot of each supernatant was transferred to an autosampler plate. The supernatant was  
211 separated via HPLC (Shimadzu VP Series 10 System) and analyzed via MS/MS (Applied  
212 Biosystems/MDS SciEx API 4000). Detection and accuracy were assessed in surrogate matrices  
213 (PBS + bovine serum albumin [BSA], charcoal stripped serum). Each surrogate matrix was  
214 spiked with 30 and 300 ng/ml of GNA (Omicron Biochemicals, Inc.; catalog number AAG-003),  
215 processed and analyzed to determine recovery and accuracy. The processed samples were  
216 analyzed by LC/MS/MS using a HILIC column. GNA was quantified using d3-GNA ( $\beta$ -D-  
217 GlcN[2H3]Ac-(1,N)-Asn) as an internal standard (IS). The calibration range was 5 to 2500  
218 ng/mL using 20  $\mu$ L of sample. The analyte/IS peak area ratios (y) versus the nominal analyte  
219 concentrations (x) of the calibration samples were used to fit a calibration curve by power  
220 regression (origin excluded). The analyte concentrations for the calibration standards, quality  
221 control samples, and unknown (study) samples were calculated using the established calibration  
222 equation.

### 223 **Statistical methodology**

224 This NHS was descriptive; thus, data were considered hypothesis-generating and not subjected to  
225 power analysis. Demographic data and baseline disease characteristics were summarized for all  
226 enrolled participants. Clinical and biological data were summarized over the study period. Data

227 were presented descriptively, and regression and/or ANOVA analyzes were performed to  
228 characterize disease course and any associated markers.

229 GNA biomarker data was analyzed using R (version 3.5.1 (2018-07-02) -- "Feather Spray")

230 Scripts available upon request.

## 231 **Results**

### 232 **Participant Disposition and Demographics**

233 The study enrolled 29 participants with a confirmed diagnosis of NGLY1 Deficiency, 15 onsite  
234 participants and 14 remote participants. The data presented here expand on the baseline  
235 characteristics and on the disposition of those reported by [Levy 2022](#). Three participants died  
236 during the study period ([Table 1](#)). All other patients remained in the study throughout its  
237 duration. Participants were followed for a median of 23 months, with a range of 8-32 months.  
238 Because participants entered the study at different times, they were followed for varying lengths  
239 of time up to the study end date. Thus, the number of patients at each time point is provided  
240 when describing the results.

241 The mean age [range] of participants was 9.93 [1-27] years at entry and 7.1 [0-16.1] years at  
242 diagnosis. The mean weight [range] expressed as Z-score was -2.08 [-0.57 to -3.97], thus  
243 indicating for all participants body weights below the norm for age.

#### 244 **Table 1: Participant Disposition and Demographics**

<b>Demographic</b>	
Number of participants – n	29
- Onsite – n (%)	15 (51.7)
- Remote – n (%)	14 (49.3)
Discontinuations during study – n (%)	None

<b>Demographic</b>	
Deaths during study – n (%)	3 (10.3)
Age at death – age range (number)	10-15 years (2); 20-25 years (1)
Age at: mean (SD)[range] – years	
- Study entry	9.93 (6.279)[1-27]
- Diagnosis	7.1 years (5.45)[0 – 16.1]
Gender – n (%)	29 (100%)
- Male	15 (51.7)
- Female	14 (49.3)
Weight as Z-score - n (%)	15 (52%)
Mean (SD) [range]	-2.1 (0.97) [-0.57 to -3.97]

245

246 **Developmental Assessments**


247 *Mullen Scales of Early Learning (MSEL)*

248 Participants who were given the MSEL had profound global developmental delays, with most  
 249 developmental quotient (DQ) scores below 20, indicating a developmental age much lower than  
 250 the normative score of 100 +/- 15 (**Figure 1**). No participant showed improvement in DQ over  
 251 time. Generally, the DQ scores were slightly declining over time for individual participants.


252 All MSEL subscales were also profoundly impaired and generally without remarkable  
 253 improvement; age equivalents were lowest in expressive language and highest in visual reception  
 254 (data on file).

255

256



268 nor clinically meaningful; participants generally remained severely impaired. Two participants,  
 269 subjects were higher functioning in several subdomains relative to other participants.



270


271 **Figure 2: Vineland ABC**

272 Legend: Individual participant Vineland ABC scores over time are shown. The normative value is 100 +/- 15  
 273 (shaded area). Black symbols are female and gray symbols are male subjects.

274 ***Peabody Developmental Motor Scales – 2<sup>nd</sup> Edition (PDMS-2)***


275 Participants assessed for the Peabody Developmental Motor Scales – 2<sup>nd</sup> Edition (PDMS-2) had  
 276 clinically significant impairments in all subscales of gross and fine motor function, The PDMS-2  
 277 provides a more detailed analysis of gross and fine motor skills in children from birth to 71  
 278 months of age. All participants who could be assessed with PDMS-2 showed marked impairment

279 in DQ for Gross Motor (Figure 3A) and Fine Motor (Figure 3B) function and had clinically  
280 significant impairments in all subscales of gross and fine motor function. For example, Grasping  
281 age equivalence was at or below 8 months and Object Manipulation age equivalence was below  
282 or at 20 months (data on file), even though chronologic age was as high as 260 months (~21  
283 years old). These data illustrate a profound impairment in upper extremity function in study  
284 participants. Profound motor impairment was also observed in all other PDMS-2 domains (data  
285 on file). While there were small changes over time for many participants, the profound motor  
286 impairments were generally stable or worsening over time.



287





288

289

### 290 **Figure 3: PDMS-2 Gross Motor (A) and Fine Motor (B) Function**

291 Legend: Individual participant PDMS-2 Gross Motor (A) and Fine Motor (B) Function scores over time are shown.  
292 The normative values are 100 +/-15. Black symbols are female and gray symbols are male subjects.

293

### 294 **Clinical Disease Course Over Time**

#### 295 ***Motor Function Parameters (Sitting and Standing Ability)***

296 Motor function was significantly impaired and showed progression over time (Table 2). At  
297 baseline, 92.3% of participants were able to sit unaided, but by Year 2 this percentage declined  
298 to 60.0%. Correspondingly, the proportion of participants requiring support or who were unable  
299 to sit increased by Year 2. Less than half of participants (38.5%) were able to stand unaided at  
300 baseline, and the percentage declined further at Year 2 to 26.7%. Additionally, the proportion of

301 participants requiring maximal support or unable to stand increased by Year 2. Review of  
302 individual participant data confirmed that the worsening trends were due to several participants  
303 whose function declined over time ([Figure 4](#)).


304 **Table 2: Motor Function Parameters**


Parameter	Timeframe*	
	Baseline n/N (%)	First Annual n/N (%)
<b>Sitting Ability</b>		
Sits unaided	12/13 (92.3)	9/15 (60.0)
Sits with minimal support	0/13 (0.0)	4/15 (26.7)
Sits with maximal support	0/13 (0.0)	1/15 (6.7)
Unable to sit	1/13 (7.7)	1/15 (6.7)
<b>Standing Ability</b>		
Stands unaided	5/13 (38.5)	4/15 (26.7)
Stands with minimal support	2/13 (15.4)	2/15 (13.3)
Stands with maximal support	5/13 (38.5)	7/15 (46.7)
Unable to stand	1/13 (7.7)	2/15 (13.3)

305

306

307





322

323 **Figure 5: Schirmer's Lacrimation Test**

324 Legend: Results from left eye. Wetting of  $\leq 5$  mm per 5 minutes is considered a strong positive test for (hypo)alacrima (Li et al  
325 2012). Greater than 10 mm is considered normal (gray line).

326 **Other Endpoints**

327 *10-Meter Walk Test (10-MWT)*

328 Only half of participants were able to attempt the 10-MWT twice or more at the comfortable  
329 speed at baseline, and the majority (84.6%) were not able to attempt the fast speed trial. As there  
330 were too few participants for the data to be clinically meaningful, the results are not shown here.

331 *Nerve Conduction Studies (NCS)*

332 Interpretation of motor and sensory conduction studies showed a mixed polyneuropathy for most  
 333 patients. Nerve conduction velocity of the median nerve for motor and sensory nerves generally  
 334 showed values below normal values reported in the literature (Ryan 2019). Of the 18 participants  
 335 with NCS assessment, 8 (44%) had at least one median nerve assessment that was not  
 336 measurable (data on file).

337 ***Quantitative Measures of Autonomic Function: Quantitative Sudomotor Axon Reflex Test***  
 338 ***(QSART)***

339 The Quantitative Sudomotor Axon Reflex Test (QSART) measures postganglionic sympathetic  
 340 sudomotor sweat response. Decreased sweat volume and increased latency (time to onset of  
 341 sweating) is indicative of peripheral autonomic neuropathy. Participants showed a decreased  
 342 sweat response (Table 3), with forearm latency and volume shown as a representative location.  
 343 Mean sweat latency in the forearm was in the high normal to elevated range, indicating delayed  
 344 sweating (normal values for sweat latency are 60-120 seconds; Illigens 2009). Mean sweat  
 345 volume in the forearm was in the low normal range at baseline and worsened to below normal at  
 346 Year 2 (normal values for sweat volume are 0.38-2.86  $\mu\text{L}$  in men and 0.10-1.99  $\mu\text{L}$  in women;  
 347 Novak, 2011). Other body locations showed generally similar findings (data on file).

348 **Table 3: Summary Statistics of QSART**

QSART Domain	Timeframe*	
	Baseline Year 1	Annual Year 2
<b>Forearm Latency (sec)</b>		
n	10	5
Mean (SD)	109.0 (52.05)	173.0 (81.00)
Median	100.5	173.0
Min, Max	20, 177	68, 290
<b>Forearm Sweat Volume (<math>\mu\text{L}</math>)</b>		
n	10	5
Mean (SD)	0.5364 (0.45795)	0.0801 (0.05811)
Median	0.4363	0.0490
Min, Max	0.047, 1.638	0.042, 0.179


349

## 350 **Quality of Life**

351 Caregiver self-reports for the caregiver's QoL per SF-36 did not show change over time (data on  
352 file).

### 353 *Pediatric Quality of Life Inventory (PedsQL)*

354 The Pediatric Quality of Life Inventory (PedsQL) is a measure of pediatric HRQoL ([Hullmann  
355 2011](#)). Total scores for participants at baseline ([Figure 6](#)) ranged from 33.7 to 95.7, with a mean  
356 of 50.5, which is lower than total scores for normal development (mean 82.5 to 95.2, depending  
357 on gender and age group; [Valier 2017](#)). Scores by domain were lowest for the Physical domain,  
358 with a mean (SD) score of 32.57 (24.924) and highest for the Emotional domain, with a mean  
359 (SD) score of 68.75 (20.283) (data on file). The PedsQL total score ([Figure 6](#)) and subdomain  
360 scores remained generally stable over time (data on file).



361

362 **Figure 6: PedsQL (Total Score) vs. Visit**

363 Legend: Black symbols are female and gray symbols are male subjects.

364


365 ***Most Bothersome Symptom***

366 When asked to describe the most bothersome symptom of NGLY1 Deficiency, caregivers  
 367 identified trouble with language/communication (for 13 patients), followed by gross or fine  
 368 motor deficits, including limited functional hand use (for caregivers of 11 patients) (data on file).

369 ***GNA levels***

370 GNA levels were elevated in the plasma of all participants, did not correlate with age, and  
 371 showed minimal change over time (Figure 7). There was no significant linear relationship  
 372 between age and GNA levels, as indicated by the horizontal black line, suggesting GNA levels

373 (GNA concentration in plasma) remain consistent over time. For onsite participants, mean (SD)  
374 GNA plasma concentration was 115 (28.4) ng/mL with range of 57.8 – 189.0 ng/mL, which was  
375 4.3-fold over related controls (unaffected siblings and parents) and 8.5-fold over unrelated  
376 unaffected controls (Mueller 2022). Longitudinal GNA samples (n=10) showed  $\leq 37$  ng/mL  
377 change over 2-3 years (max – min concentration; mean change 23.0 ng/mL +/- 10.8 ng/mL).



378


379 **Figure 7: Plasma GNA Concentration vs. Age at Collection for Participants as Measured**  
380 **over Time**

381 Legend: Age at sample collection and GNA concentration were compared to determine whether there was a significant  
382 relationship. The line is the trend line with statistical correlation shown. Each red point represents a measurement and red points  
383 with short black lines between them are measurements for the same participant.  
384

385 **Laboratory Studies**




386 Laboratory study results were generally unremarkable, except for ALT (Figure 8) and AST  
387 (Figure 9) levels, which were elevated in some participants. Those with elevated ALT/AST  
388 values showed improvement over time, especially among the younger patients. The liver  
389 transaminases were not associated with elevated total bilirubin levels and did not reach levels  
390 indicative of severe liver disease.



391

392 **Figure 8: ALT (U/L) vs Chronological Age**

393 Legend: If participants had multiple lab measurements at the same visit, the highest value was selected for analysis.



394

395 **Figure 9: AST (U/L) vs Chronological Age**

396 Legend: If participants had multiple lab measurements at the same visit, the highest value was selected for analysis.

## 397 Discussion

398 This prospective NHS was undertaken to characterize the clinical characteristics, disease course,  
399 and potential clinical trial endpoints for NGLY1 Deficiency, a severely debilitating, ultra-rare,  
400 autosomal recessive, neurodevelopmental disorder. Consistent with previous publications, the  
401 core features of the disease, global developmental delay and/or intellectual disability, a  
402 hyperkinetic movement disorder, transient elevation of transaminases, and (hypo)alacrima  
403 (Adams 2018; Enns 2014; Lam 2018; Levy 2022) were found to be profound and did not show  
404 spontaneous improvements, as with typical childhood development over time. The natural  
405 history was generally slowly progressive or at best stable over at least a 1-year period. This  
406 publication reports on neurodevelopmental outcomes, disease course over time, laboratory  
407 studies, HRQoL and biomarkers. Mortality is also reported, pointing to the urgency for

408 development of treatments for this devastating disease. This report complements findings on  
409 seizures and EEG results previously reported from this NHS ([Levy 2022](#)).

410 All participants in this NHS had profound neurodevelopmental impairment as demonstrated by  
411 developmental and adaptive skills assessments using standard validated instruments, the MSEL  
412 and Vineland 3. Profound impairment was observed in the composite score and in all domains,  
413 encompassing expressive and receptive language as well as coping skills and interpersonal  
414 relationships. There was a trend in neurodevelopmental outcomes, such that those participants  
415 with epilepsy (>50% of participants) had more severe developmental delay ([Levy 2022](#)). While  
416 there were minor fluctuations over time with the neurocognitive instruments (MSEL and  
417 Vineland 3) across all domains assessed, these were not clinically significant and were generally  
418 within the expected variability of measurement. There was no evidence of spontaneous  
419 improvements and the participants failed to recover functional abilities typical for their  
420 chronological age. Rather, individuals with NGLY1 Deficiency either slowly deteriorated further  
421 or remained at a level of profound impairment. In clinical trials of potential therapies for NGLY1  
422 Deficiency, improvements in neurocognitive assessments could signify treatment efficacy;  
423 however, even a stabilization or halting of decline based on these assessments could be  
424 considered a beneficial effect of treatment.

425 Nearly all participants exhibited failure to thrive, manifesting as low weight for age, and motor  
426 impairments consisting of delayed/absent attainment of motor milestones as shown on physical  
427 exam, PDMS-2, and motor subdomains of the MSEL and Vineland-3. Both gross and fine motor  
428 skills were severely impaired. Worsening of already poor gross motor function over time was  
429 indicated by the reduction in the proportion of participants who achieved unaided sitting or  
430 standing with concurrent increased proportions of participants who could not sit or stand. There

431 were no spontaneous improvements in the ability to sit or stand even though participants were at  
432 or older than the ages where these gross motor milestones are expected to be achieved. The  
433 ability to sit and stand independently would be expected to greatly impact a patient's and their  
434 caregiver's quality of life. Overall, multiple assessment methods pointed toward slowly  
435 progressive declines in motor abilities required for self-care and activities of daily living. The  
436 motor function results of this NHS suggest that if motor abilities are used as an endpoint in  
437 future therapeutic trials, any improvements seen are more likely to be due to the efficacy of the  
438 therapy rather than natural improvement with age, and that even a small improvement would be  
439 clinically important, given the profound impairment that begins early in life and may worsen  
440 over time.

441 Schirmer's test for lacrimation (tear formation) and QSART assessments (sweat response) also  
442 indicated impaired functions in participants. These assessments are indicative of autonomic  
443 dysfunction in NGLY1 Deficiency ([Lam 2018](#); [Pinto 2020](#); [Willems 2022](#)) and were generally  
444 stable or worsened over time. Insufficient tear production has an important impact on health in  
445 individuals with NGLY1 Deficiency and is associated with corneal damage, including  
446 neovascularization, pannus formation, and scarring ([Lam 2018](#)). Reduced sweat response  
447 (hypohydrosis) requires protective measures against situations that could cause dangerous core  
448 body hyperthermia ([Lam 2017](#)), such as cooling vests and adequate access to water and air  
449 conditioning ([Lam 2018](#)).

450 The majority of participants had impaired HRQoL as measured by PedsQL that showed no clear  
451 change over time by total score or by subdomain. Symptoms that were most troublesome to  
452 caregivers included difficulties with language/communication and motor deficits (particularly  
453 limited functional hand use). The caregivers' impressions are consistent with the deficits seen on

454 the MSEL, which showed profound impairment in language and communication, the Vineland-3,  
455 which showed extensive impairment in gross and fine motor skills, and the PDMS-2, which  
456 showed clinically important impairment in all measures of gross and fine motor skills including  
457 grasp and object manipulation. Caregiver-reported improvement in the symptoms that most  
458 directly affect the HRQoL of participants and their families could represent meaningful  
459 secondary endpoints.

460 GNA has been identified as a substrate biomarker for NGLY1 Deficiency ([Mueller 2022](#)).  
461 Unlike other potential biomarkers for NGLY1 Deficiency ([Lam 2017](#); [Hall 2018](#); [Chang 2019](#)),  
462 GNA is a substrate biomarker that directly results from the lack of NGLY1 function. consistently  
463 differentiates those individuals affected by NGLY1 Deficiency from those without NGLY1  
464 Deficiency ([Mueller 2022](#)). Individuals with the inherited metabolic disease  
465 aspartylglucosaminuria (AGU) also show elevated GNA levels but can be distinguished from  
466 those with NGLY1 Deficiency through genetic testing and consideration of key clinical features.  
467 The data presented in this report demonstrate that GNA was elevated in all NHS participants and  
468 remained stable over time. In a rat model of NGLY1 Deficiency, virally-mediated delivery of a  
469 functional human copy of the NGLY1 gene led to a reduction in GNA levels that correlated with  
470 improvement of behavior and locomotor phenotypes ([Mueller 2022](#), [Zhu 2022](#)). A similar  
471 restoration of NGLY1 function as assessed by normalization of GNA levels might be used as a  
472 key endpoint to measure treatment effect and be expected to predict clinical benefit in future  
473 NGLY1 gene therapy clinical trials.

474 Liver transaminases were mildly elevated at baseline and stable or, in the case of some younger  
475 patients, improved over time. This is consistent with previous reports of NGLY1 Deficiency in  
476 which liver dysfunction has been identified as an important phenotype of the disease ([Need](#)

477 [2012](#); [Heeley 2015](#); [Lipinski 2020](#); [Rios-Flores 2020](#); [Lipari 2020](#)). Although AST/ALT levels  
478 were not high enough to be indicative of severe liver disease in this NHS, they should be  
479 followed over time during future interventional studies as part of safety monitoring and,  
480 concurrently, may be an important clinical measure to evaluate for treatment efficacy ([Pandey](#)  
481 [2022](#)).

482 The current study has some limitations. Because patients entered the study at different times,  
483 they had different durations of follow-up data. Year 3 study data were only available for a small  
484 subset of patients, thus limiting statistical analyses and conclusions about long-term disease  
485 progression. The COVID-19 pandemic delayed or precluded some on-site study visits, which  
486 impacted the availability of some data. In addition, patients were not able to perform all of the  
487 planned assessments, such as the Beery-Buktenica Test of Visual Motor Integration and the 10-  
488 MWT, due to the profound neurological and physical impairments associated with NGLY1  
489 Deficiency.

490 The data presented here provide valuable insights about the clinical course of NGLY1  
491 Deficiency. The sample size of 29 participants in this NHS represents a substantial proportion of  
492 the population of approximately 100 identified individuals with NGLY1 Deficiency ([Enns 2014](#);  
493 [Pandey 2022](#); data on file). This study demonstrates that the profound neurodevelopmental  
494 impairments, quality of life, and other outcomes of NGLY1 Deficiency do not improve and often  
495 decline over at least a one-year period, despite existing interventions like physical therapy and  
496 symptom management. This dataset informs endpoints, selection of assessment tools, and  
497 monitoring intervals for interventional clinical trials. Such assessments include GNA levels as a  
498 pharmacodynamic biomarker, instruments that measure language/communication and motor  
499 deficits (particularly improved hand use), HRQoL, clinical/caregiver global impressions of

500 change, tear production, and QSART. Seizures and neurophysiologic characterization are also  
501 relevant because, as previously described, almost all participants had EEG abnormalities,  
502 indicating increased risk of epilepsy ([Levy 2022](#)). As the overall disease course shows a slow but  
503 progressive decline in neurocognitive and motor function, interventions that result in  
504 stabilization or a slowing of the decline in function could be considered as efficacious.

## 505 **Declaration of interest**

506 Authors S.S.D., S.T., W.F.M., B.J.B., and M.W. are employees of Grace Science, LLC. K.J.L. is  
507 a consultant for Grace Science Foundation.

## 508 **Acknowledgements**

509 Funding for this study was provided by a grant from Grace Science Foundation (GSF) to  
510 Stanford University. Dr Maura Ruzhnikov contributed to protocol development and was the  
511 principal investigator of the study. Dr Stephen Maricich reviewed and analyzed preliminary data.  
512 Medical writing, editing, and design assistance was provided by Judy Wiles, Trish Rawn, and  
513 Selma Tse of Facet Communications Inc. Caroline Stanclift served as a liaison between GSF and  
514 the trial site; graphic presentations were provided by Alicia Newton.

## 515 **Author contributions**

516 Conceptualization: S.S.D., W.F.M., B.J.B., M.W., K.J.L., J.K.; Study coordination: M.W.,  
517 C.H.F.; Data curation: S.S.D., W.F.M.; Formal analysis: S.T., P.V., S.S.D., W.F.M., C.H.F., S.M;  
518 Investigation: S.D.D., W.R.M., J.K., J.P., C.H.F., S.M.; Visualization: S.T., W.F.M., K.J.L.;

519 Writing-original draft: S.T., P.V., S.S.D., W.F.M; Writing-review & editing: S.T., P.V., S.S.D.,  
520 W.F.M., B.J.B., M.W., K.J.L, J.K., J.P., C.H.F.

## 521 **Data and code availability**

522 The datasets that support this study are available from the corresponding author upon reasonable  
523 request, subject to institution ethical considerations for participant privacy and consent.

## 524 **Ethical Approval**

525  
526 Informed consent was obtained from all study participants according to the study protocol  
527 approved by the Stanford Institutional Review Board (IRB Protocol # 47335). Parents gave  
528 written informed consent for their children or dependents.

## 529 **References**

530 Adams, J., and Schaaf, C.P. (2018) Diagnosis and genetics of alacrima. *Clin. Genet.* *94*, 54–60

531 Aylward, G.P., Jeffries, L.M., et al. (2008) Mullen Scales of Early Learning. *Developmental-*  
532 *Behavioral Pediatrics*, *Ch 7*, 123-201.

533 Cahan, E. M., Frick, S.L. (2019) Orthopaedic phenotyping of NGLY1 deficiency using an  
534 international, family-led disease registry. *Orphanet J Rare Dis*, *14*, article number: 148.

535 Chang C.A., Wei X.C., Martin S.R., Sinasac D.S., Al-Hertani W. Transiently elevated plasma  
536 methionine, S-adenosylmethionine and S-adenosylhomocysteine: Unreported laboratory findings  
537 in a patient with NGLY1 deficiency, a congenital disorder of deglycosylation. *JIMD Rep.* 2019;  
538 49:21–29. doi: 10.1002/jmd2.12064.



- 539 Dabaj I, Sudrié-Arnaud B, Lecoquierre F, et al. NGLY1 deficiency: A rare newly described  
540 condition with a typical presentation. *Life*. 2021;11:187. <https://doi.org/10.3390/life11030187>.
- 541 de Baptista, Cynthia R J A et al. (2020) Methods of 10-Meter Walk Test and Repercussions for  
542 Reliability Obtained in Typically Developing Children. *Rehabilitation research and practice*  
543 *2020 4209812*.
- 544 Enns GM, Shashi V, Bainbridge M, et al. (2014) Mutations in NGLY1 cause an inherited  
545 disorder of the endoplasmic reticulum-associated degradation pathway. *Genet Med*. *16(10)*, 751-  
546 758.
- 547 Farmer, C., Adedipe , D., Bal, V., et al. (2020) Concordance of the Vineland Adaptive Behaviour  
548 Scales, Second and Third Editions. *J Intellect Disabil Res*. *64(1)*, 18-26.
- 549 Haijes, H.A., de Sain-van der Velden, M.G.M., Prinsen, H., et al (2019) Aspartylglycosamine is  
550 a biomarker for NGLY1-CDDG, a congenital disorder of deglycosylation. *Mol. Genet. Metab*.  
551 **127**, 368–372.
- 552 Hall, P.L., Lam, C., Alexander, J.J., Asif, G., Berry, G.T., Ferreira, C., Freeze, H.H., Gahl, W.A.,  
553 Nickander, K.K., Sharer, J.D., Watson, C.M., Wolfe, L., and Raymond, K.M. (2018) Urine  
554 oligosaccharide screening by MALDI-TOF for the identification of NGLY1 deficiency. *Mol*.  
555 *Genet. Metab*. **124**, 82–86.
- 556 Heeley J., Shinawi M. Multi-systemic involvement in NGLY1-related disorder caused by two  
557 novel mutations. *Am. J. Med. Genet. A*. 2015;167A:816–820.

- 558 Hullmann SE, Ryan JL, Ramsey RR, et al. Measures of general pediatric quality of life. *Arthritis*  
559 *Care & Research*. 2011; 63(S11):S420-S430.
- 560 Illigens BMW, Gibbons CH. Sweat testing to evaluate autonomic function. *Clin Auton Res*.  
561 2009;19(2):79-87.
- 562 Kalfon L, Baydany M, Samra , et al. Congenital Hypotonia: Cracking a SAGA of  
563 consanguineous kindred harboring four genetic variants. *Mol Genet Genomic Med*.  
564 2022;10:e1849.
- 565 Karampatakis, V., Karamitsos, A., Skriapa, A., Pasiadis, G. (2010) Comparison between normal  
566 values of 2- and 5-minute Schirmer test without anesthesia. *Cornea*, 29(5), 497-501.
- 567 Lam C, Ferreira C, Krasnewich D, et al. Prospective phenotyping of NGLY1-CDDG, the first  
568 congenital disorder of deglycosylation. *Genet Med*. 2017;19(2):160-168.
- 569 Lam C, Wolfe L, Need A, et al. *NGLY1*-Related Congenital Disorder of Deglycosylation. *Gene*  
570 *Reviews*. 2018; <https://www.ncbi.nlm.nih.gov/sites/books/NBK481554/>.
- 571 Levy RJ, et al. Delineating the epilepsy phenotype of NGLY1 deficiency. *JIMD*. 2022;  
572 <https://doi.org/10.1002/jimd.12494>.
- 573 Li N, Deng XG, He MF. Comparison of the Schirmer I test with and without topical anesthesia for  
574 diagnosing dry eye. *Int J Ophthalmol*. 2012; 5(4):478-481.
- 575 Lipari Pinto P., Machado C., Janeiro P., Dupont J., Quintas S., Sousa A.B., Gaspar A. NGLY1  
576 deficiency—A rare congenital disorder of deglycosylation. *JIMD Rep*. 2020;53:2–9.  
577 doi: 10.1002/jmd2.12108

- 578 Lipiński P., Cielecka-Kuszyk J., Socha P., Tyłki-Szymanska A. Liver involvement in NGLY1  
579 congenital disorder of deglycosylation. *Pol. J. Pathol.* 2020;71:66–68.  
580 doi: 10.5114/pjp.2020.92994.
- 581 Mueller WF, Zhu L, Tan B, et al. GlcNAc-Asn is a biomarker for NGLY1 deficiency. *J*  
582 *Biochem.* 2022;171(2):177-186. doi:10.1093/jb/mvab111. Accessed 31 October 2022:  
583 <https://academic.oup.com/jb/article/171/2/177/6410260>
- 584 Need A.C., Shashi V., Hitomi Y., Schoch K., Shianna K.V., McDonald M.T., Meisler M.H.,  
585 Goldstein D.B. Clinical application of exome sequencing in undiagnosed genetic conditions. *J.*  
586 *Med. Genet.* 2012; 49:353–361. doi: 10.1136/jmedgenet-2012-100819.
- 587 Novak P. Quantitative autonomic testing. *Journal of Visualized Experiments.* 2011. doi:  
588 10.3791/2502
- 589 Pandey A, Adams JM, Han SY, Jafar-Nejad H. NGLY1 Deficiency, a Congenital Disorder of  
590 Deglycosylation: From Disease Gene Function to Pathophysiology. *Cells.* 2022;11(7):1155.
- 591 Pereira AC, Ribeiro MC, Araujo APQC. (2016) Timed motor function tests capacity in healthy  
592 children. *Arch Dis Child.* **101**;147-151.
- 593 Pinto, P. L., Machado, C., Janiero, P., et al. (2020) NGLY1 deficiency – a rare congenital  
594 disorder of glycosylation. *JIMD Rep*, 53(1): 2-9.
- 595 RAND Corporation. 36-item short form survey (SF-36): scoring instructions.  
596 [https://www.rand.org/health-care/surveys\\_tools/mos/36-item-short-form/scoring.html](https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html). Accessed  
597 July 12, 2022.

- 598 Rebelo M, Serrano J, Duarte-Mendes P, et al. Evaluation of the Psychometric Properties of the  
599 Portuguese Peabody Developmental Motor Scales-2 Edition: A Study with Children Aged 12 to  
600 48 Months. *Children (Basel)*. 2021;8(11):1049.
- 601 Rios-Flores I.M., Bonal-Perez M.A., Castellanos-Gonzalez A., Velez-Gomez E., Bertoli-Avella  
602 A.M., Bobadilla-Morales L., Pena-Padilla C., Appendini-Andrade V., Corona-Rivera A.,  
603 Romero-Valenzuela I., et al. Acute liver failure in a male patient with NGLY1-congenital  
604 disorder of deglycosylation. *Eur. J. Med. Genet.* 2020;63:103952.  
605 doi: 10.1016/j.ejmg.2020.103952.
- 606 Ryan, C.S., Conlee, E.M., Sharma, R., et al. Nerve conduction normal values for  
607 electrodiagnosis in pediatric patients. *Muscle Nerve*. 2019;60(2):155-160.
- 608 Spencer, T.D., Kruse, L. Beery-Buktenica Developmental Test of Visual Motor Integration.  
609 (2010) *Encyclopedia of Autism Spectrum Disorders*. In: Volkmar, F.R. (eds) *Encyclopedia of*  
610 *Autism Spectrum Disorders*. Springer, New York, NY. [https://doi.org/10.1007/978-1-4419-](https://doi.org/10.1007/978-1-4419-1698-3_1886)  
611 [1698-3\\_1886](https://doi.org/10.1007/978-1-4419-1698-3_1886).
- 612 Stuu T, Popescu O, Oviedo A (October 29, 2021) N-Glycanase 1 Deficiency is a rare cause of  
613 pediatric neurodegeneration with neuronal inclusions and liver steatosis. *Cureus* 13(10): e19126.
- 614 Suzuki, T., Huang, C., and Fujihira, H. (2016) The cytoplasmic peptide:N-glycanase (NGLY1) –  
615 structure, expression and cellular functions. *Gene* 577, 1–7.
- 616 Valier ARS, Bacon CEW, Bay RC, et al. Reference values for the Pediatric Quality of Life Scale  
617 Inventory and the Multidimensional Fatigue Scale in adolescent athletes by sport and sex. *Am J*  
618 *Sports Med.* 2017;45(12):2723-2729.

619 Willems, M., Wells, C. F., Coubes, C., et al. (2022) Hypoalacrima and alacrima as diagnostic  
620 features for genetic or congenital conditions. *Investigative Ophthalmology & Visual Science*, 63  
621 3.

622 Zhu L, Tan B, Dwight S, et al. AAV9-NGLY1 gene replacement therapy improves phenotypic  
623 and biomarker endpoints in a rat model of NGLY1 Deficiency. *Meth Clinical Dev.*, 2022;27:269-  
624 271. doi:<https://doi.org/10.1016/j.omtm.2022.09.015>:  
625 <https://www.sciencedirect.com/science/article/pii/S2329050122001401>